Protara Therapeutics Inc (TARA) - Net Assets
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has net assets worth $196.41 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($209.47 Million) and total liabilities ($13.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Protara Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $196.41 Million |
| % of Total Assets | 93.77% |
| Annual Growth Rate | 35.94% |
| 5-Year Change | 21.31% |
| 10-Year Change | 410.94% |
| Growth Volatility | 845.35 |
Protara Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Protara Therapeutics Inc (TARA) total assets for the complete picture of this company's asset base.
Annual Net Assets for Protara Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Protara Therapeutics Inc from 2012 to 2025. For live valuation and market cap data, see Protara Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $196.41 Million | +17.52% |
| 2024-12-31 | $167.13 Million | +144.63% |
| 2023-12-31 | $68.32 Million | -33.07% |
| 2022-12-31 | $102.08 Million | -36.95% |
| 2021-12-31 | $161.91 Million | -18.74% |
| 2020-12-31 | $199.24 Million | +3017.07% |
| 2019-12-31 | $6.39 Million | -68.73% |
| 2018-12-31 | $20.44 Million | -41.15% |
| 2017-12-31 | $34.74 Million | -9.63% |
| 2016-12-31 | $38.44 Million | -39.37% |
| 2015-12-31 | $63.41 Million | -23.11% |
| 2014-12-31 | $82.46 Million | +2106.81% |
| 2013-12-31 | $-4.11 Million | -213.20% |
| 2012-12-31 | $3.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Protara Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21576200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $54.00K | 0.03% |
| Other Comprehensive Income | $90.00K | 0.05% |
| Other Components | $498.69 Million | 253.90% |
| Total Equity | $196.41 Million | 100.00% |
Protara Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Protara Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
West Wits Mining Ltd
AU:WWI
|
$282.52 Million |
|
Omega Flex Inc
NASDAQ:OFLX
|
$282.54 Million |
|
AVE Science & Technology Co Ltd
SHG:688067
|
$282.60 Million |
|
Ring Energy Inc
NYSE MKT:REI
|
$282.68 Million |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
$282.32 Million |
|
Cellectis
PA:ALCLS
|
$282.27 Million |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
$282.15 Million |
|
Idun Industrier AB Series B
ST:IDUN-B
|
$282.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Protara Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 167,134,000 to 196,412,000, a change of 29,278,000 (17.5%).
- Net loss of 57,439,000 reduced equity.
- New share issuances of 80,964,000 increased equity.
- Other comprehensive income increased equity by 88,000.
- Other factors increased equity by 5,665,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.44 Million | -29.24% |
| Share Issuances | $80.96 Million | +41.22% |
| Other Comprehensive Income | $88.00K | +0.04% |
| Other Changes | $5.67 Million | +2.88% |
| Total Change | $- | 17.52% |
Book Value vs Market Value Analysis
This analysis compares Protara Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.55x to 1.16x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $9.68 | $5.32 | x |
| 2013-12-31 | $-10.96 | $5.32 | x |
| 2014-12-31 | $252.78 | $5.32 | x |
| 2015-12-31 | $154.04 | $5.32 | x |
| 2016-12-31 | $92.84 | $5.32 | x |
| 2017-12-31 | $80.44 | $5.32 | x |
| 2018-12-31 | $7.98 | $5.32 | x |
| 2019-12-31 | $1.57 | $5.32 | x |
| 2020-12-31 | $27.54 | $5.32 | x |
| 2021-12-31 | $14.41 | $5.32 | x |
| 2022-12-31 | $9.07 | $5.32 | x |
| 2023-12-31 | $6.03 | $5.32 | x |
| 2024-12-31 | $8.12 | $5.32 | x |
| 2025-12-31 | $4.59 | $5.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Protara Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-29.24%) is above the historical average (-71.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -219.56% | 0.00% | 0.00x | 2.14x | $-8.33 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.50 Million |
| 2014 | -4.05% | -113.36% | 0.03x | 1.03x | $-11.59 Million |
| 2015 | -33.72% | 0.00% | 0.00x | 1.07x | $-27.72 Million |
| 2016 | -74.21% | 0.00% | 0.00x | 1.13x | $-32.37 Million |
| 2017 | -86.25% | 0.00% | 0.00x | 1.27x | $-33.44 Million |
| 2018 | -124.43% | 0.00% | 0.00x | 1.15x | $-27.48 Million |
| 2019 | -234.54% | 0.00% | 0.00x | 1.09x | $-15.63 Million |
| 2020 | -17.05% | 0.00% | 0.00x | 1.02x | $-53.90 Million |
| 2021 | -29.18% | 0.00% | 0.00x | 1.07x | $-63.44 Million |
| 2022 | -64.61% | 0.00% | 0.00x | 1.11x | $-76.16 Million |
| 2023 | -59.16% | 0.00% | 0.00x | 1.16x | $-47.25 Million |
| 2024 | -26.68% | 0.00% | 0.00x | 1.09x | $-61.31 Million |
| 2025 | -29.24% | 0.00% | 0.00x | 1.07x | $-77.08 Million |
Industry Comparison
This section compares Protara Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Protara Therapeutics Inc (TARA) | $196.41 Million | -219.56% | 0.07x | $282.32 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more